CD274 and neoplasm: Despite the remarkable clinical success of anti-PD-1/PD-L1 immunotherapy, it is unclear whether these inhibitors have the same effects on restoring anti-tumor immunity, resulting in the difficulty in choosing the best inhibitor in the clinic.